Intra-individual, randomized comparison of the MRI contrast agents Gadovist 1.0 versus Prohance in patients with primary and secondary brain tumors, evaluated in a blinded read.

Trial Profile

Intra-individual, randomized comparison of the MRI contrast agents Gadovist 1.0 versus Prohance in patients with primary and secondary brain tumors, evaluated in a blinded read.

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 27 Jul 2011

At a glance

  • Drugs Gadobutrol (Primary) ; Gadoteridol
  • Indications Brain cancer
  • Focus Diagnostic use
  • Most Recent Events

    • 27 Jul 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top